FDA has extended the review time for glucagon rescue pensfrom Danish Zealand Pharma's US rivals. Zealand's Chief Medical and Development Officer, Adam Steensberg, calls it beneficial for the company and is not scared of encountering the same problems.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.